Adiponectin has different mechanisms in type 1 and type 2 diabetes with C-peptide link

Ljubic, Spomenka; Boras, Jozo; Jazbec, Anamarija; Lovrencic, Marijana Vucic; Vidjak, Vinko; Erzen, Dubravka Jurisic; Mileta, Dean
August 2009
Clinical & Investigative Medicine;Aug2009, Vol. 32 Issue 4, pE271
Academic Journal
Purpose: Adiponectin (ApN) is considered to be responsible for reduction of inflammation and is known to be included in lipid metabolism. This study was designed to assess the role of adiponectin in patients with type 1 and type 2 diabetes and to determine parameters important in the prediction of adiponectin. Methods: Adiponectin, high sensitive C-reactive protein, fibrinogen, homocysteine, C-peptide, and lipid panel in addition to clinical and laboratory parameters important for the definition of diabetes, obesity and the metabolic syndrome were measured in 118 patients. Results: The best model (R²=0.989) for predicting adiponectin in type 1 diabetes included fibrinogen, white blood cell count, uric acid and triglycerides. In type 2 diabetes the best model (R²=0.751) included C-peptide, white blood cell count, systolic blood pressure, fasting blood glucose, glycated hemoglobin and high-density lipoprotein cholesterol. ANOVA showed among-group differences in adiponectin (P=0.028), body mass index (P <0.001), fasting blood glucose (P <0.001) and high-density lipoprotein cholesterol (P =0.012) according to the type of diabetes. Between-group differences were also observed in adiponectin (P =0.033) and high-density lipoprotein cholesterol (P =0.009) according to sex. Adiponectin correlated (P <0.05) with body mass index, C-peptide, pulse pressure and high-density lipoprotein cholesterol. Conclusion: Adiponectin levels were higher in type 1 diabetes. The association between C-peptide and adiponectin is probably one of the reasons for their different respective levels in different types of diabetes. Interrelations between adiponectin and inflammation, dyslipidemia, C-peptide levels and sex appear to be important for complex adiponectin modulation and action.


Related Articles

  • Atorvastatin: A Review of its Use in the Primary Prevention of Cardiovascular Events in Patients with Type 2 Diabetes Mellitus. Croom, Katherine F.; Plosker, Greg L. // Drugs;2005, Vol. 65 Issue 1, p137 

    Atorvastatin (Lipitor®) is an HMG-CoA reductase inhibitor with well documented lipid-lowering effects. It has recently been evaluated for the primary prevention of major cardiovascular events in patients with type 2 diabetes mellitus without elevated serum low-density lipoprotein...

  • Serum levels of p53 and cytochrome c in subjects with type 2 diabetes and impaired glucose tolerance. Dincer, Yildiz; Himmetoglu, Solen; Yalin, Serap; Damci, Taner; Ilkova, Hasan; Akcay, Tulay // Clinical & Investigative Medicine;Aug2009, Vol. 32 Issue 4, pE266 

    Purpose: To examine apoptotic markers in serum of subjects with diabetes and impaired glucose tolerance (IGT). Serum levels of p53 and cytochrome c, regulator molecules for apoptosis, were measured in subjects with type 2 diabetes, subjects with IGT and healthy controls. Methods: Forty one...

  • Leptin levels in obese women with and without type 2 diabetes mellitus. Akif Buyukbese, Mehmet; Cetinkaya, Ali; Kocabas, Ramazan; Guven, Aytekin; Tarakcioglu, Mehmet // Mediators of Inflammation;Oct2004, Vol. 13 Issue 5/6, p321 

    I ntroduction : The role of leptin has been more clear in the endocrinology area after the discovery of its secretion from the adipose tissue. The aim of the study is to investigate the leptin levels in obese women in whom type 2 diabetes mellitus were present or absent. Materials and methods :...

  • Pioglitazone/Metformin. Decks, Emma D.; Scott, Lesley J. // Drugs;2006, Vol. 66 Issue 14, p1863 

    â–´ A fixed-dose pioglitazone/metformin tablet is approved in the US and the EU for the treatment of adult patients with type 2 diabetes mellitus who currently have inadequate glycaemic control with metformin monotherapy. In the US, the combination tablet is also approved for the treatment...

  • Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Humpert, Per M.; Djuric, Zdenka; Kopf, Stefan; Rudofsky, Gottfried; Morcos, Michael; Nawroth, Peter P.; Bierhaus, Angelika // Cardiovascular Diabetology;2007, Vol. 6, p9 

    Background: Total circulating soluble receptor for advanced glycation endproducts (sRAGE) and a more defined endogenous secretory splice variant of the receptor (esRAGE) were shown to be associated with different markers of cardiovascular risk in patients with diabetes. Since previous data were...

  • INSULIN ACTION--INSULIN RESISTANCE IN VITRO.  // Diabetes;Jun2008 Supplement 1, Vol. 57, pA697 

    The article offers information on different studies about diabetes with topics on chronic endothelin, measurement of serum visfatin levels in patients with type 2 diabetes mellitus (T2DM), metformin, and inflammatory markers. The study on serum vistafin levels employed an enzyme-linked...

  • Plasma Retinol-Binding Protein-4 Concentrations Are Elevated in Human Subjects With Impaired Glucose Tolerance and Type 2 Diabetes. Young Min Cho; Byung-Soo Youn; Hyewon Lee; Namseok Lee; Sung-Shik Min; Soo Heon Kwak; Hong Kyu Lee; Kyong Soo Park // Diabetes Care;Nov2006, Vol. 29 Issue 11, p2457 

    OBJECTIVE -- The dysregulation of adipokines is closely associated with the pathogenesis of insulin resistance and type 2 diabetes. Retinol-binding protein-4 (RBP4), a new adipokine, was recently reported to provide a link between obesity and insulin resistance. Here, we examined the relation...

  • Heparanase Levels Are Elevated in the Urine and Plasma of Type 2 Diabetes Patients and Associate with Blood Glucose Levels. Shafat, Itay; Ilan, Neta; Zoabi, Samih; Vlodavsky, Israel; Nakhoul, Farid // PLoS ONE;2011, Vol. 6 Issue 2, p1 

    Heparanase is an endoglycosidase that specifically cleaves heparan sulfate side chains of heparan sulfate proteoglycans. Utilizing an ELISA method capable of detection and quantification of heparanase, we examined heparanase levels in the plasma and urine of a cohort of 29 patients diagnosed...

  • Anticardiolipin Antibodies in Patients with Type 2 Diabetes Mellitus. Colvo-Romero, José María; Lima-Rodríguez, Esther María // Clinical Medicine & Research;Sep2009, Vol. 7 Issue 3, p93 

    Background: There is controversy about an increased prevalence of antiphospholipid antibodies in diabetic patients. The possible implications are little known. Methods: We prospectively studied all consecutive outpatients with type 2 diabetes mellitus (DM) attended to in an Internal Medicine...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics